Kontrasepsiyonda Gen Teknolojisinin Kulanımı

Dünya genelinde çeşitli hayvan türlerindeki populasyon artışı fertilite kontrolünü zorunlu halegetirmiştir. Özellikle yaban hayatının olduğu habitatlarda av-avcı ilişkisi bozulmaktadır. Şehirhayatında ise evde bakılan ve sokak hayvanı sayısındaki hızlı artış insan/ hayvan sağlığı ve çevrehijyeni açısından pek çok probleme neden olmaktadır. Bu sorunun çözümü amacıyla geçici ya dakalıcı çeşitli kısırlaştırma uygulamaları geliştirilmektedir. Sunulan derlemede alternatif bir medikalyöntem olan gen teknolojilerinin kısırlaştırma amacıyla kullanımı güncel çalışma sonuçları ileokuyucuya sunulmuştur.

Using Gene Technology in Contraception

The increase in the population of various animal species in the world has been made necessary to fertility control. The predator-prey relationship deteriorates, especially in the wildlife. In urban life, the rapid increase in home owned and stray animals causes many problems in the human / animal health and environmental hygiene. To solve this problem, it develops various temporary or permanent sterilization approaches. In this review, as an alternative medical method, the usage of gene technologies for sterilisation is presented to readers via recent study results.

PDF

___

1. Maenhoudt C, Santos N, Fontbonne A, Suppression of fertility in adult dogs. Reprod Domest Anim 2014; 49: 58- 63.
2. Howe L. Surgical methods of contraception and sterilization. Theriogenology 2006; 66: 500-509.
3. Kutzler M, Wood A. Non-surgical methods of contraception and sterilization. Theriogenology 2006; 66: 514-525.
4. Wildt DE, Seager S. Reproduction control in dogs. Vet Clin North Am 1977; 7: 775-787.
5. Naz RK, Saver AE. Immunocontraception for animals: Current status and future perspective. Am J Reprod Immunol 2016; 75: 426-439.
6. Fire A, Xu S, Montgomery MK, et al. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 1998; 391: 806-811.
7. Zeng Y, Cullen BR. RNA interference in human cells is restricted to the cytoplasm. RNA 2002; 8: 855-860.
8. Agrawal N, Dasaradhi PVN, Mohammed A, et al. RNA interference: Biology, mechanism, and applications. Microbiol Mol Biol Rev 2003; 67: 657-685.
9. Reddy LS, Sarojamma V, Ramakrishna V. Future of RNAi in medicine: A review. World J Med Sci 2007; 2: 01 -14.
10. Herzog RW, Mount JD, Arruda VR, et al. Muscle-directed gene transfer and transient immune suppression result in sustained partial correction of canine hemophilia B caused by a null mutation. Mol Ther 2001; 4: 192-200.
11. Niemeyer GP, Herzog RW, Mount J, et al. Long-term correction of inhibitor-prone hemophilia B dogs treated with liver-directed AAV2-mediated factor IX gene therapy. Blood, J Am Soc Hematol 2009; 113: 797-806.
12. Rhodes L. New approaches to non‐surgical sterilization for dogs and cats: Opportunities and challenges. Reprod Domest Anim 2017; 52: 327-331.
13. High KA, Aubourg P. rAAV Human Trial Experience. In: Snyder R, Moullier P. (Editors). Adeno-Associated Virus. Methods in Molecular Biology (Methods and Protocols). 1st Edition, Philadelphia: Saunders 2012: 429-457.
14. Asokan A, Conway JC, Phillips JL, et al. Reengineering a receptor footprint of adeno-associated virus enables selective and systemic gene transfer to muscle. Nat Biotechnol 2010; 28: 79-82.
15. Schultz BR, Chamberlain JS. Recombinant adenoassociated virus transduction and integration. Mol Ther 2008; 16: 1189-1199.
16. Duque S, Joussemet B, Riviere C, et al. Intravenous administration of self-complementary AAV9 enables transgene delivery to adult motor neurons. Mol Ther 2009; 17: 1187-1196.
17. Foust KD, Nurre E, Montgomery CL, et al. Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes. Nat Biotechnol 2009; 27: 59.
18. Foust KD, Wang X, McGovern VL, et al. Rescue of the spinal muscular atrophy phenotype in a mouse model by early postnatal delivery of SMN. Nat Biotechnol 2010; 28: 271 -274.
19. Dominguez E, Marais T, Chatauret N, et al. Intravenous scAAV9 delivery of a codon-optimized SMN1 sequence rescues SMA mice. Hum Mol Genet 2011; 20: 681 -693.
20. Bevan AK, Duque S, Foust KD, et al. Systemic gene delivery in large species for targeting spinal cord, brain, and peripheral tissues for pediatric disorders. Mol Ther 2011; 19: 1971 -1980.
21. Fu H, DiRosario J, Killedar S, et al. Correction of neurological disease of mucopolysaccharidosis IIIB in adult mice by rAAV9 trans-blood–brain barrier gene delivery. Mol Ther 2011; 19: 1025-1033.
22. Gray SJ, Matagne V, Bachaboina L, et al. Preclinical differences of intravascular AAV9 delivery to neurons and glia: A comparative study of adult mice and nonhuman primates. Mol Ther 2011; 19: 1058-1069.
23. Dayton RD, Wang DB, Klein RL. The advent of AAV9 expands applications for brain and spinal cord gene delivery. Expert Opin Biol Ther 2012; 12: 757-766.
24. Deverman BE, Pravdo PL, Simpson BP, et al. Credependent selection yields AAV variants for widespread gene transfer to the adult brain. Nat Biotechnol 2016; 34: 204.
25. Hay BA, Li J, Guo M. Vectored gene delivery for lifetime animal contraception: Overview and hurdles to implementation. Theriogenology 2018; 112: 63-74.
26. Lehman MN, Coolen LM, Goodman RL. Minireview: Kisspeptin/neurokinin B/dynorphin (KNDy) cells of the arcuate nucleus: A central node in the control of gonadotropin-releasing hormone secretion. Endocrinology 2010; 151: 3479-3489.
27. Navarro VM, Gottsch ML, Wu M, et al. Regulation of NKB pathways and their roles in the control of Kiss1 neurons in the arcuate nucleus of the male mouse. Endocrinology 2011; 152: 4265-4275.
28. de Tassigny XDA, Fagg LA, Dixon JP, et al. Hypogonadotropic hypogonadism in mice lacking a functional Kiss1 gene. Proc Natl Acad Sci 2007; 104: 10714-10719.
29. Navarro VM. Interactions between kisspeptins and neurokinin B. In: Kauffman AS, Smith JT. (Editors). Kisspeptin Signaling in Reproductive Biology. 1st Edition, New York: Springer 2013: 325-347.
30. Kotani M, Detheux M, Vandenbogaerde A, et al. The metastasis suppressor gene KiSS-1 encodes kisspeptins, the natural ligands of the orphan G protein-coupled receptor GPR54. J Biol Chem 2001; 276: 34631 -34636.
31. Ohtaki T, Shintani Y, Honda S, et al. Metastasis suppressor gene KiSS-1 encodes peptide ligand of a Gprotein-coupled receptor. Nature 2001; 411: 613-617.
32. Funes S, Hedrick JA, Vassileva G, et al. The KiSS-1 receptor GPR54 is essential for the development of the murine reproductive system. Biochem Biophys Res Commun 2003; 312: 1357-1363.
33. Semple RK, Achermann JC, Ellery J, et al. Two novel missense mutations in g protein-coupled receptor 54 in a patient with hypogonadotropic hypogonadism. J Clin Endocrinol Metab 2005; 90: 1849-1855.
34. Clarkson J, de Tassigny XDA, Moreno AS, et al. Kisspeptin–GPR54 signaling is essential for preovulatory gonadotropin-releasing hormone neuron activation and the luteinizing hormone surge. J Neurosci 2008; 28: 8691 -8697.
35. Topaloglu AK, Reimann F, Guclu M, et al. TAC3 and TACR3 mutations in familial hypogonadotropic hypogonadism reveal a key role for Neurokinin B in the central control of reproduction. Nat Genet 2009; 41: 354.
36. Silveira LG, Tusset C, Latronico AC. Impact of mutations in kisspeptin and neurokinin B signaling pathways on human reproduction. Brain Res 2010; 1364: 72-80.
37. Dissen GA, Adachi K, Lomniczi A, et al. Engineering a gene silencing viral construct that targets the cat hypothalamus to induce permanent sterility: An update. Reprod Domest Anim 2017; 52: 354-358.
38. Li J, Olvera AI, Akbari OS, et al. Vectored antibody gene delivery mediates long-term contraception. Curr Biol 2015; 25: R820-R822.
39. Kano M, Sosulski AE, Zhang L, et al. AMH/MIS as a contraceptive that protects the ovarian reserve during chemotherapy. Proc Natl Acad Sci 2017; 114: E1688- E1697.
40. Tsutsui K, Bentley GE, Bedecarrats G, et al. Gonadotropin-inhibitory hormone (GnIH) and its control of central and peripheral reproductive function. Front Neuroendocrinol 2010; 31: 284-295.
41. Durlinger A, Visser J, Themmen A. Regulation of ovarian function: The role of anti-Mullerian hormone. Reproduction 2002; 124: 601 -609.
42. Kim JH, MacLaughlin DT, Donahoe PK, Müllerian inhibiting substance/anti-Müllerian hormone: A novel treatment for gynecologic tumors. Obstet Gynecol Sci 2014; 57: 343-357.
43. Monniaux D, Clément F, Dalbiès-Tran R, et al. The ovarian reserve of primordial follicles and the dynamic reserve of antral growing follicles: what is the link? Biol Reprod 2014; 90: 85-91.
44. McLennan IS, Pankhurst MW. Anti-Mullerian hormone is a gonadal cytokine with two circulating forms and cryptic actions. J Endocrinol 2015; 226: R45-R57.
45. Boonthum C, Namdee K, Boonrungsiman S, et al. Chitosan-based DNA delivery vector targeted to gonadotropin-releasing hormone (GnRH) receptor. Carbohydr Polym 2017; 157: 311 -320.
46. Roesl C, Jeffery N, Smith S. Single injection steriltity via lentiviral-mediated suppression of androgen receptors in Sertoli cells. in Abstract presented at the ISCFR-EVSSAR Congress, Paris, France. 2016.